The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 16 September 2021. Please click to review the
Imagion Biosystems is pleased to provide its investors with its September 2021 Investor Newsletter. The newsletter details recent new company developments and activities, including: Message
The document “Application for quotation of +securities” was lodged with ASX on 9 September, 2021. Please click to review the full announcement at ASX.
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 9 September 2021. Please click to review the
The document “Application for quotation of +securities” was lodged with ASX on 26 August 2021. Please click to review the full announcement at ASX.
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 26 August 2021. Please click to review the
The document “Notification of cessation of +securities” was lodged with ASX on 24 August, 2021. Please click to review the full announcement at ASX.
1H2021 Highlights: Enrolment for the Phase I HER2 Breast Cancer Study commences Initiation of research for prostate cancer imaging supported by CSIRO funds Collaboration with
The document “Application for Quotation of +Securities” was lodged with ASX on 15 August 2021. Please click to review the full announcement at ASX.
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 15 August 2021. Please click to review the
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance